Journal of Parasitic Diseases: Diagnosis and Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Perspective - Journal of Parasitic Diseases: Diagnosis and Therapy (2025) Volume 10, Issue 3

Immunodiagnostics: Revolutionizing the Fight against Parasitic Diseases

Fatima Al-Mansouri*

Department of Medical Parasitology, Qatar University, Qatar

Corresponding Author:
Fatima Al-Mansouri
Department of Medical Parasitology,
Qatar University,
Qatar
E-mail: fatima.mansouri@qu.edu.qa

Received: 02-Aug-2025, Manuscript No. AAPDDT-25-166615; Editor assigned: 03-Aug-2025, AAPDDT-25-166615 (PQ); Reviewed: 17-Aug-2025, QC No. AAPDDT-25-166615; Revised: 22-Aug-2025, Manuscript No. AAPDDT-25-166615 (R); Published: 30-Aug-2025, DOI:10.35841/2591-7846.10.3.235

Citation: Al-Mansouri F. Immunodiagnostics: revolutionizing the fight against parasitic diseases, J Parasit Dis Diagn Ther. 2025; 10(3):235

Introduction

Parasitic diseases continue to pose significant public health challenges worldwide, especially in tropical and subtropical regions. Early and accurate diagnosis is critical for effective treatment and control of these infections. Immunodiagnostics has emerged as a powerful tool in parasitology, leveraging the host’s immune response to detect the presence of parasites [1, 2, 3, 4].

Immunodiagnostics refers to the use of immunological techniques to identify parasitic infections by detecting specific antigens, antibodies, or immune complexes in clinical samples such as blood, serum, or cerebrospinal fluid. Unlike traditional microscopic methods, which rely on direct visualization of parasites, immunodiagnostic tests offer enhanced sensitivity and specificity [5, 6].

Especially in low-parasite load scenarios or chronic infections. Common immunodiagnostic approaches include enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence assay (IFA), rapid diagnostic tests (RDTs), and Western blotting. ELISA remains the most widely used technique due to its high throughput capacity, quantitative results, and adaptability to various parasitic diseases such as malaria, leishmaniasis, toxoplasmosis, and schistosomiasis. Rapid diagnostic tests have revolutionized point-of-care diagnosis by providing quick and user-friendly detection, critical in resource-limited settings. These lateral flow immunochromatographic assays detect parasite-specific antigens or antibodies within minutes without the need for sophisticated laboratory infrastructure. Despite these advances, immunodiagnostics face challenges such as cross-reactivity with related parasites, persistence of antibodies after infection clearance, and variability in immune responses among individuals. Ongoing research focuses on identifying novel parasite-specific biomarkers and improving assay accuracy to overcome these limitations [7, 8, 9, 10].

Conclusion

Immunodiagnostics plays an indispensable role in the diagnosis and management of parasitic diseases. Continued innovation in immunological assays promises improved disease surveillance, timely treatment, and better control strategies to reduce the global burden of parasitic infections.

References

  1. Hussein M, Molina MA, Berkhout B, et al. A CRISPR-Cas Cure for HIV/AIDS. Int J Mol Sci. 2023;24(2):1563.

    2. Indexed at, Google Scholar, Cross Ref

  2. Bhowmik R, Chaubey B. CRISPR/Cas9: a tool to eradicate HIV-1. 2022;19(1):58.

    3. Indexed at, Google Scholar, Cross Ref

  3. Fozouni P, Son S, de León Derby MD, et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell. 2021;184(2):323-33.

    4. Indexed at, Google Scholar, Cross Ref

  4. Pandey M, Ojha D, Bansal S, et al. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Mol Aspects Med. 2021;81:101003.

    5. Indexed at, Google Scholar, Cross Ref

  5. Nidhi S, Anand U, Oleksak P, et al. Novel CRISPR–Cas systems: an updated review of the current achievements, applications, and future research perspectives. Int J Mol Sci. 2021;22(7):3327.

    6. Indexed at, Google Scholar, Cross Ref

  6. Qu J, Kalyani FS, Liu L, et al. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy. Cancer Commun (Lond). 2021;41(12):1331-53.

    7. Indexed at, Google Scholar, Cross Ref

  7. Gleerup JL, Mogensen TH. CRISPR-Cas in diagnostics and therapy of infectious diseases. J Infect Dis. 2022;226(11):1867-76.

    8. Indexed at, Google Scholar, Cross Ref

  8. Dubey AK, Mostafavi E. Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy. Front Chem. 2023;11.

    9. Indexed at, Google Scholar, Cross Ref

  9. Binnie A, Fernandes E, Almeida-Lousada H, et al. CRISPR-based strategies in infectious disease diagnosis and therapy. Infection. 2021;49:377-85.

    10. Indexed at, Google Scholar, Cross Ref          

  10. Grosch M, Schraft L, Chan A, et al. Striated muscle-specific base editing enables correction of mutations causing dilated cardiomyopathy. Nat Commun. 2023;14(1):3714.

    11. Indexed at, Google Scholar, Cross Ref

Get the App